Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target

Sep 29, 2026, 3:43 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 29, 2026, 12:07 PMBenzinga Newsdesk
Acurx Pharmaceuticals Says First Patient Enrolled In New PATHFINDER Clinical Trial In Patients With Multiply Recurrent C. Difficile Infection
PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in
ACXP
BenzingaSep 18, 2026, 12:03 PMBenzinga Insights
Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call
Acurx Pharmaceuticals (NASDAQ:ACXP) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access
ACXP
BenzingaSep 8, 2026, 8:39 PMBenzinga Newsdesk
Acurx Pharmaceuticals Files Prospectus For 1.5M Offering
ACXP